SKIP TO CONTENT
About Abbott
Contact
International | eng
Country Language

CARDIOVASCULAR

International | eng
Country Language

Esprit™ BTK

Everolimus Eluting Resorbable Scaffold

Esprit BTK

Take a Stand Against CLTI for Your Patients

Choose the new standard of care for BTK treatment that delivers superior results without compromising safety.


Chronic Limb-Threatening Ischemia (CLTI) is a severe form of peripheral artery disease (PAD) that can lead to amputation and increased mortality/cardiovascular events.1  Now, Abbott's Esprit™ BTK System offers a breakthrough innovation for you and your patients as the first-and-only FDA-approved drug-eluting resorbable scaffold for CLTI. With reduced restenosis and reinterventions,3,6,7 and significant improvement in primary patency and limb salvage,3,6 you can be confident you're giving your patients the state-of-the-art standard of care.

Interested to learn more?

Back to top

Deliver superior results for your patients without compromising their safety

"The durability of this result has never been demonstrated with any BTK technology previously."

-Sahil Parikh, MD, New York-Presbyterian/Columbia University Irving Medical Center

48% Fewer Patients Require Reintervention6,7

  • Esprit™ BTK System patients have 48% fewer reinterventions vs. PTA at 2 years (9.7% vs 18.6%)
  • 90.3% of Esprit™ BTK patients did not require a reintervention through 2 years
Fewer patients require reintervention

Superior Efficacy, Sustained Benefits through 2 Years3,6

  • 31% improvement (74.5% vs. 43.7%) in limb salvage and primary patency at 1 year, with sustained benefits through 2 years
  • Demonstrated to be as safe as PTA through 2 years in the LIFE-BTK study
Superior efficacy sustained through 2 years

Proven Primary Treatment6

  • Addresses vessel recoil and dissection4, with radial strength similar to a metallic stent within the first 6 months8
  • Inhibits restenosis and maximizes patency through sustained everolimus elution5
  • Preserves flexibility for the future with complete resorption9
Proven primary treatment
Learn More About the LIFE-BTK Study
BTK technology

The LIFE-BTK Study, published in the New England Journal of Medicine, is the first successful RCT to demonstrate superiority of an interventional device over standard of care for treatment of BTK disease in CLTI patients. The 2-year data demonstrated sustained efficacy and safety.3,6

Life BTK study

Back to top

Life btk study
Life btk study

Take BTK Treatment in Stride with State-of-the-Art Care

Watch how the Esprit™ BTK System does it all for CLTI: addressing vessel recoil and dissection,4 combined with a drug to inhibit neointimal hyperplasia,5 and then fully resorbs over time,9 preserving future treatment options.

Learn More About the Features

Back to top

Case Studies: A Giant Step Forward in BTK Treatment

Physicians share their experience with the Esprit™ BTK System and the advantages it delivers in treating their patients and improving outcomes.

Esprit BTK is a new paradigm for limb salvage intervention, creating opportunities for sustained patency and increased pedal perfusion pressure to heal the wound after the first intervention. - Matthew C. Bunte, MD., MS
Esprit BTK is fundamentally changing how I treat my patients with tibial disease - finally we have a tool that offers our patients hope and substantially better outcomes. - J.D. Corl, MD
Read Case Studies

Back to top

Back to top

Sharing Information, Promoting Understanding:

Resources to Help Your Patients Walk Away from PAD/CLTI

Beyond the treatment, make sure your referring physicians are fully aware of PAD and CLTI and how they can help with early diagnosis and timely treatment. For information specifically for the physician, visit our Clear Program webpage. Access a full range of helpful tools and insights. 
 


Back to top

Ordering Information

Diameter182838Sheath (F)1Maximum Post-Dilation Diameter1Nominal/RBP Inflation Pressure4
2.5 mm1203250-181203250-281203250-385F (0.070"/1.8 mm)3.0 mm9/16 ATM
3.0 mm1203300-181203300-281203300-385F (0.070"/1.8 mm)3.5 mm9/16 ATM
3.5 mm1203350-181203350-281203350-385F (0.070"/1.8 mm)4.0 mm9/16 ATM
3.75 mm1203375-181203375-281203375-385F (0.070"/1.8 mm)4.25 mm9/16 ATM

This device is commercially available for use in select international markets. Check the regulatory status in your geography.

Back to top

References

  1. Farber, A., Menard, M. T., Bonaca, M. P., Bradbury, A., Conte, M. S., Debus, E. S., ... & Rosenfield, K. (2024). BEST-CLI International Collaborative: planning a better future for patients with chronic limb-threatening ischaemia globally. British Journal of Surgery, 111(2), znad413.
  2. Zeller, T., Rastan, A., Macharzina, R., Pilger, E., Schwarzwälder, U., & Bürgelin, K. (2007). Long-term results after balloon angioplasty of tibial artery obstructions in patients with critical limb ischemia. Journal of Vascular and Interventional Radiology, 18(7), 841-849. doi:10.1016/j.jvir.2007.03.014. Retrieved from https://www.jvir.org/article/S1051-0443(07)00292-5/fulltext00292-5/fulltext).
  3. Varcoe, RL., et al. Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease. N Eng J Med 2024;390:9-19.
  4. Esprit™ BTK Everolimus Eluting Resorbable Scaffold System Instructions for Use (IFU). Refer to IFU for additional information.
  5. Data on file at Abbott.
  6. Brian G. DeRubertis et al., Two-Year Outcomes of the LIFE-BTK Randomized Controlled Trial Evaluating the Esprit™ BTK Drug-eluting Resorbable Scaffold for Treatment of Infrapopliteal Lesions, VIVA 2024.
  7. Reintervention defined as CD-TLR.
  8.  Data on file at Abbott. Testing done with XIENCE Sierra™ 3.5 x 38 mm at nominal.
  9. Data on file at Abbott. Excluding platinum markers.

MAT-2405960 v5.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
Abbott logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2025 Abbott. All Rights Reserved.

MAT-2001111 v8.0

Disclaimer

You are about to enter an Abbott country- or region-specific website. 

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

Do you wish to continue and enter this website? 

YES

MAT-2305078 v1.0